GLP1R and metabolic disease: The development of various metabolic diseases including obesity, hypertension, and diabetes have been closely linked to Lachnoclostridium (Zang et al. 2023; Zhao et al. 2023), which can be increased by GLP-1 receptor agonists used to treat diabetes (Tsai et al. 2021).